All In Biotech

Drug Trial Radar · NCT06870422

To Assess the Effect of the Special Condition on the Pharmacokinetics and Tolerability of the Esflurbiprofen Topical System (EFTS) in Healthy Volunteers.

A Randomized, Four-way Change-over Study to Evaluate the Effect of Moderate Heat, Occlusion, and Moderate Exceise on the Pharmacokinetics and Tolerability of the Esflurbiprofen Topical System in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Apr 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

Feb 28, 2025

Primary completion

Apr 3, 2025

Study completion Apr 14, 2025

Sponsor

Lead sponsor
Teikoku Seiyaku Co., Ltd.Industry
Sponsor type
Industry
Collaborators
SocraTec R&D GmbH; SocraMetrics GmbH; HWI pharma services GmbH
First posted
Mar 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a single-center, open-label, single-dose trial performed in a randomized, four-way, change-over design in healthy volunteers. The primary purpose of this study is to evaluate the effect of moderate heat, occlusion, and moderate exercise on pharmacokinetics. The secondary purpose is to characterize the effect of special conditions on the bioavailability and to evaluate patch adhesion and safety of TK-254RX and a residual amount of the patch.

Conditions

  • Healthy

Interventions

  • Esflurbiprofen Topical SystemDrug

    TK-254RX will be applied for one day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessing the effect of each intervention by Area under the plasma concentration versus time curve over 24 hours (AUC0-24) of S-flurbiprofenTime frame: Day 1 to Day 2 for each period
  2. Assessing the effect of each intervention by peak plasma concentration (Cmax) of S-flurbiprofenTime frame: Day 1 to Day 2 for each period
  3. Assessing the effect of each intervention by area under the plasma concentration versus time curve from patch application to last measurement time point with a concentration value above lower limit of quantitation (AUC0-tlast) of S-flurbiprofenTime frame: Day 1 to Day 4 for each period
  4. Assessing the effect of each intervention by area under the plasma concentration versus time curve from patch application to infinity (AUC0-inf) of S-flurbiprofenTime frame: Day 1 to Day 4 for each period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • SocraTec R&D GmbH Clinical Pharmacology Unit

    Mainzerhofplatz, Erfurt, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.